Published in Nat Rev Cancer on September 01, 2005
ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol (2008) 11.86
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev (2007) 6.35
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68
Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol (2011) 3.65
Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 3.49
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature (2007) 3.21
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
Clinical implications of the cancer genome. J Clin Oncol (2010) 3.11
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77
Mutational status of naevus-associated melanomas. Br J Dermatol (2015) 2.68
Homologous recombination and its regulation. Nucleic Acids Res (2012) 2.44
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell (2008) 2.38
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35
Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal (2009) 2.33
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A (2008) 2.27
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
The basic cleft of RPA70N binds multiple checkpoint proteins, including RAD9, to regulate ATR signaling. Mol Cell Biol (2008) 2.17
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) (2014) 2.10
In-silico human genomics with GeneCards. Hum Genomics (2011) 2.10
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med (2014) 2.03
Function of a conserved checkpoint recruitment domain in ATRIP proteins. Mol Cell Biol (2007) 2.02
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. Proc Natl Acad Sci U S A (2008) 2.01
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Combination chemical genetics. Nat Chem Biol (2008) 1.98
Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol (2006) 1.97
Cancer vulnerabilities unveiled by genomic loss. Cell (2012) 1.95
Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med (2013) 1.94
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
Systematic genome instability screens in yeast and their potential relevance to cancer. Proc Natl Acad Sci U S A (2007) 1.90
Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat Cell Biol (2012) 1.89
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res (2012) 1.87
Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest (2007) 1.80
Genome-scale gene/reaction essentiality and synthetic lethality analysis. Mol Syst Biol (2009) 1.69
Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer (2009) 1.69
The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One (2013) 1.69
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A (2009) 1.66
Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet (2006) 1.66
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature (2013) 1.66
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol (2011) 1.65
Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A (2012) 1.65
Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol (2010) 1.62
Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med (2011) 1.56
Targeting the RB-pathway in cancer therapy. Clin Cancer Res (2010) 1.54
Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res (2008) 1.53
DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell (2010) 1.52
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med (2011) 1.52
Existing and emerging technologies for tumor genomic profiling. J Clin Oncol (2013) 1.52
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med (2009) 1.49
Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol (2010) 1.47
Novel anticancer strategy targets DNA repair. Nat Rev Drug Discov (2009) 1.47
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One (2008) 1.46
Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest (2011) 1.46
Human RECQ helicases: roles in DNA metabolism, mutagenesis and cancer biology. Semin Cancer Biol (2010) 1.44
DNA damage and decisions: CtIP coordinates DNA repair and cell cycle checkpoints. Trends Cell Biol (2010) 1.44
Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle (2009) 1.44
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med (2012) 1.44
Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol (2010) 1.43
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer (2016) 1.41
Using functional genetics to understand breast cancer biology. Cold Spring Harb Perspect Biol (2010) 1.39
Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett (2010) 1.39
Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res (2010) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. Cancer Res (2009) 1.27
Targeting p53 for Novel Anticancer Therapy. Transl Oncol (2010) 1.26
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol (2014) 1.26
Cancer cells and normal cells differ in their requirements for Thoc1. Cancer Res (2007) 1.26
Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov (2013) 1.25
Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol (2012) 1.24
Modeling synthetic lethality. Genome Biol (2008) 1.23
PARP-1 and PARP-2: New players in tumour development. Am J Cancer Res (2011) 1.23
Structures of YAP protein domains reveal promising targets for development of new cancer drugs. Semin Cell Dev Biol (2012) 1.19
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res (2014) 1.18
Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol (2010) 1.17
A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet (2014) 1.17
Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther (2011) 1.16
Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med (2009) 1.16
Conserved RB functions in development and tumor suppression. Protein Cell (2011) 1.15
Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med (2011) 1.13
The splicing-factor related protein SFPQ/PSF interacts with RAD51D and is necessary for homology-directed repair and sister chromatid cohesion. Nucleic Acids Res (2010) 1.12
Biology-driven cancer drug development: back to the future. BMC Biol (2010) 1.12
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res (2013) 1.09
Targeting cancer with a lupus autoantibody. Sci Transl Med (2012) 1.09
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? Clin Cancer Res (2015) 1.08
Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia (2011) 1.08
New challenges in high-energy particle radiobiology. Br J Radiol (2014) 1.08
Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci (2012) 1.07
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07